vs
IHS Holding Ltd（IHS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
IHS Holding Ltd的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$254.0M vs $207.3M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 0.1%），IHS Holding Ltd自由现金流更多（$178.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -22.0%）
IHS Holding是全球规模领先的共享通信基础设施独立持有、运营及开发企业之一，也是全球第五大独立跨国通信铁塔企业，业务覆盖非洲与拉美地区，为当地通信网络部署提供关键的铁塔基础设施支持。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
IHS vs RARE — 直观对比
营收规模更大
IHS
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出25.8%
0.1%
自由现金流更多
IHS
多$279.4M
$-100.8M
两年增速更快
RARE
近两年复合增速
-22.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $254.0M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 83.6% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 0.1% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IHSRARE
| Q4 25 | $254.0M | $207.3M | ||
| Q3 25 | $455.1M | $159.9M | ||
| Q2 25 | $433.3M | $166.5M | ||
| Q1 25 | $439.6M | $139.3M | ||
| Q4 24 | $253.8M | $164.6M | ||
| Q3 24 | $420.3M | $139.5M | ||
| Q2 24 | $435.4M | $147.0M | ||
| Q1 24 | $417.7M | $108.8M |
净利润IHSRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $147.4M | $-180.4M | ||
| Q2 25 | $32.3M | $-115.0M | ||
| Q1 25 | $30.7M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-205.7M | $-133.5M | ||
| Q2 24 | $-124.3M | $-131.6M | ||
| Q1 24 | $-1.6B | $-170.7M |
毛利率IHSRARE
| Q4 25 | 83.6% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 51.3% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 52.0% | — | ||
| Q2 24 | 52.5% | — | ||
| Q1 24 | 39.1% | — |
营业利润率IHSRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | 35.1% | -106.9% | ||
| Q2 25 | 33.8% | -64.8% | ||
| Q1 25 | 37.1% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 29.9% | -94.6% | ||
| Q2 24 | 34.0% | -79.1% | ||
| Q1 24 | -1.7% | -151.9% |
净利率IHSRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 32.4% | -112.8% | ||
| Q2 25 | 7.5% | -69.0% | ||
| Q1 25 | 7.0% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -48.9% | -95.7% | ||
| Q2 24 | -28.5% | -89.5% | ||
| Q1 24 | -372.8% | -156.8% |
每股收益（稀释后）IHSRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $0.44 | $-1.81 | ||
| Q2 25 | $0.10 | $-1.17 | ||
| Q1 25 | $0.10 | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $-0.61 | $-1.40 | ||
| Q2 24 | $-0.36 | $-1.52 | ||
| Q1 24 | $-4.67 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $825.7M | $421.0M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $-89.8M | $-80.0M |
| 总资产 | $4.5B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IHSRARE
| Q4 25 | $825.7M | $421.0M | ||
| Q3 25 | $647.6M | $202.5M | ||
| Q2 25 | $531.8M | $176.3M | ||
| Q1 25 | $629.0M | $127.1M | ||
| Q4 24 | $578.0M | $174.0M | ||
| Q3 24 | $397.5M | $150.6M | ||
| Q2 24 | $445.7M | $480.7M | ||
| Q1 24 | $333.2M | $112.3M |
总债务IHSRARE
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $3.2B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.6B | — | ||
| Q1 24 | $3.5B | — |
股东权益IHSRARE
| Q4 25 | $-89.8M | $-80.0M | ||
| Q3 25 | $38.1M | $9.2M | ||
| Q2 25 | $-98.4M | $151.3M | ||
| Q1 25 | $-184.4M | $144.2M | ||
| Q4 24 | $-314.4M | $255.0M | ||
| Q3 24 | $-284.7M | $346.8M | ||
| Q2 24 | $-308.3M | $432.4M | ||
| Q1 24 | $-163.2M | $140.3M |
总资产IHSRARE
| Q4 25 | $4.5B | $1.5B | ||
| Q3 25 | $4.7B | $1.2B | ||
| Q2 25 | $4.5B | $1.3B | ||
| Q1 25 | $4.4B | $1.3B | ||
| Q4 24 | $4.2B | $1.5B | ||
| Q3 24 | $4.6B | $1.5B | ||
| Q2 24 | $4.5B | $1.6B | ||
| Q1 24 | $4.6B | $1.3B |
负债/权益比IHSRARE
| Q4 25 | — | — | ||
| Q3 25 | 85.85× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $246.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $178.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 70.3% | -48.6% |
| 资本支出强度资本支出/营收 | 26.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $718.7M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流IHSRARE
| Q4 25 | $246.9M | $-99.8M | ||
| Q3 25 | $251.3M | $-91.4M | ||
| Q2 25 | $237.7M | $-108.3M | ||
| Q1 25 | $200.3M | $-166.5M | ||
| Q4 24 | $344.4M | $-79.3M | ||
| Q3 24 | $174.5M | $-67.0M | ||
| Q2 24 | $134.7M | $-77.0M | ||
| Q1 24 | $75.8M | $-190.7M |
自由现金流IHSRARE
| Q4 25 | $178.6M | $-100.8M | ||
| Q3 25 | $189.2M | $-92.7M | ||
| Q2 25 | $197.7M | $-110.7M | ||
| Q1 25 | $153.2M | $-167.8M | ||
| Q4 24 | $282.9M | $-79.5M | ||
| Q3 24 | $122.3M | $-68.6M | ||
| Q2 24 | $74.2M | $-79.0M | ||
| Q1 24 | $14.8M | $-193.9M |
自由现金流率IHSRARE
| Q4 25 | 70.3% | -48.6% | ||
| Q3 25 | 41.6% | -58.0% | ||
| Q2 25 | 45.6% | -66.5% | ||
| Q1 25 | 34.8% | -120.5% | ||
| Q4 24 | 111.5% | -48.3% | ||
| Q3 24 | 29.1% | -49.2% | ||
| Q2 24 | 17.0% | -53.7% | ||
| Q1 24 | 3.5% | -178.2% |
资本支出强度IHSRARE
| Q4 25 | 26.9% | 0.5% | ||
| Q3 25 | 13.6% | 0.8% | ||
| Q2 25 | 9.2% | 1.5% | ||
| Q1 25 | 10.7% | 1.0% | ||
| Q4 24 | 24.2% | 0.1% | ||
| Q3 24 | 12.4% | 1.2% | ||
| Q2 24 | 13.9% | 1.4% | ||
| Q1 24 | 14.6% | 3.0% |
现金转化率IHSRARE
| Q4 25 | — | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 7.36× | — | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IHS
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
